Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes

by Jagan A. Pillai, Jagan A. Pillai, Jagan A. Pillai, Maria Khrestian, Maria Khrestian, James Bena, James B. Leverenz, James B. Leverenz, James B. Leverenz, Lynn M. Bekris, Lynn M. Bekris
Published 2021-06-01

Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer’s and Lewy body neuropathology

by Jagan A. Pillai, James Bena, Aaron Bonner-Jackson, James B. Leverenz
Published 2021-01-01

TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease

by Jagan A. Pillai, Jagan A. Pillai, Jagan A. Pillai, Gurkan Bebek, Gurkan Bebek, Maria Khrestian, Maria Khrestian, James Bena, Cornelia C. Bergmann, William S. Bush, James B. Leverenz, James B. Leverenz, James B. Leverenz, Lynn M. Bekris, Lynn M. Bekris
Published 2021-02-01

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery

by Yadi Zhou, Jiansong Fang, Lynn M. Bekris, Young Heon Kim, Andrew A. Pieper, James B. Leverenz, Jeffrey Cummings, Feixiong Cheng
Published 2021-01-01

Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases.

by Atsuro Uchida, Jagan A Pillai, Robert Bermel, Stephen E Jones, Hubert Fernandez, James B Leverenz, Sunil K Srivastava, Justis P Ehlers
Published 2020-01-01

Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease

by Jagan A. Pillai, Sean Maxwell, James Bena, Lynn M. Bekris, Stephen M. Rao, Mark Chance, Bruce T. Lamb, James B. Leverenz, for the Alzheimer’s Disease Neuroimaging Initiative
Published 2019-07-01

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment

by Yadi Zhou, Jielin Xu, Yuan Hou, James B. Leverenz, Asha Kallianpur, Reena Mehra, Yunlong Liu, Haiyuan Yu, Andrew A. Pieper, Lara Jehi, Feixiong Cheng
Published 2021-06-01

Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry

by Hojoong M. Kim, James B. Leverenz, Daniel J. Burdick, Sindhu Srivatsal, Jennifer Pate, Shu-Ching Hu, Steven P. Millard, Marie Y. Davis, Ali Samii, Cyrus P. Zabetian
Published 2018-01-01

Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures

by Hojoong M. Kim, Carter Nazor, Cyrus P. Zabetian, Joseph F. Quinn, Kathryn A. Chung, Amie L. Hiller, Shu-Ching Hu, James B. Leverenz, Thomas J. Montine, Karen L. Edwards, Brenna Cholerton
Published 2019-01-01

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

by Nicole F Liachko, Pamela J McMillan, Timothy J Strovas, Elaine Loomis, Lynne Greenup, Jill R Murrell, Bernardino Ghetti, Murray A Raskind, Thomas J Montine, Thomas D Bird, James B Leverenz, Brian C Kraemer
Published 2014-12-01

Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease

by Jagan A. Pillai, James Bena, Gurkan Bebek, Lynn M. Bekris, Aaron Bonner‐Jackson, Lei Kou, Akshay Pai, Lauge Sørensen, Mads Neilsen, Stephen M. Rao, Mark Chance, Bruce T. Lamb, James B. Leverenz, the Alzheimer’s Disease Neuroimaging Initiative
Published 2020-07-01

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

by Lana M Chahine, Liz Urbe, Chelsea Caspell-Garcia, Dag Aarsland, Roy Alcalay, Paolo Barone, David Burn, Alberto J Espay, Jamie L Hamilton, Keith A Hawkins, Shirley Lasch, James B Leverenz, Irene Litvan, Irene Richard, Andrew Siderowf, Christopher S Coffey, Tanya Simuni, Daniel Weintraub, Parkinson’s Progression Markers Initiative
Published 2018-01-01

Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting

by Jennifer G. Goldman, Bradley F. Boeve, Melissa J. Armstrong, Doug R. Galasko, James E. Galvin, David J. Irwin, James B. Leverenz, Karen Marder, Victor Abler, Kevin Biglan, Michael C. Irizarry, Bill Keller, Robert Lai, Leanne Munsie, Michael Belleville, Ondrea Chaney, Ian Richard, Angela Taylor, Todd Graham
Published 2021-07-01

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

by Carlos Cruchaga, John S K Kauwe, Kevin Mayo, Noah Spiegel, Sarah Bertelsen, Petra Nowotny, Aarti R Shah, Richard Abraham, Paul Hollingworth, Denise Harold, Michael M Owen, Julie Williams, Simon Lovestone, Elaine R Peskind, Ge Li, James B Leverenz, Douglas Galasko, Alzheimer's Disease Neuroimaging Initiative, John C Morris, Anne M Fagan, David M Holtzman, Alison M Goate
Published 2010-09-01